Combinatorial Cancer Immunotherapy

Advances in Immunology

Volumn 90, Issue , 2006, Pages 341-368

  Hodi, F Stephen ^a   Dranoff, Glenn ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTIBODY; ATP6S1 ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR ANTIGEN; TUMOR CELL VACCINE; UNCLASSIFIED DRUG;

APOPTOSIS; AUTOIMMUNE DISEASE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; GENE TRANSFER; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; LUNG CARCINOMA; PRIORITY JOURNAL; REVIEW;

ANIMALS; CANCER VACCINES; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS;

EID: 33646756539     PISSN: 00652776     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2776(06)90009-1     Document Type: Review

References (156)

1. 5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. 188 (1998) 1359-1368
2. Andersen M.H., Becker J.C., and Straten P. Identification of an HLA-A3-restricted cytotoxic T lymphocyte (CTL) epitope from ML-IAP. J. Invest. Dermatol. 122 (2004) 1336-1337
3. Andersen M.H., Pedersen L.O., Becker J.C., and Straten P.T. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res. 61 (2001) 869-872
4. Andersen M.H., Pedersen L.O., Capeller B., Brocker E.B., Becker J.C., and thor Straten P. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res. 61 (2001) 5964-5968
5. Andersen M.H., Reker S., Becker J.C., and thor Straten P. The melanoma inhibitor of apoptosis protein: A target for spontaneous cytotoxic T cell responses. J. Invest. Dermatol. 122 (2004) 392-399
6. Andrade F., Roy S., Nicholson D., Thornberry N., Rosen A., and Casciola-Rosen L. Granzyme B directly and efficiently cleaves several downstream caspase substrates: Implications for CTL-induced apoptosis. Immunity 8 (1998) 451-460
7. Antin J.H. Graft-versus-leukemia: No longer an epiphenomenon. Blood 82 (1993) 2273-2277
8. Ashhab Y., Alian A., Polliack A., Panet A., and Yehuda D.B. Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. FEBS Lett. 495 (2001) 56-60
9. Assikis V.J., and Simons J.W. Novel therapeutic strategies for androgen-independent prostate cancer: An update. Semin. Oncol. 31 (2004) 26-32
10. Barks J.H., Thompson F.H., Taetle R., Yang J.M., Stone J.F., Wymer J.A., Khavari R., Guan X.Y., Trent J.M., Pinkel D., and Nelson M.A. Increased chromosome 20 copy number detected by fluorescence in situ hybridization (FISH) in malignant melanoma. Genes Chromosomes Cancer 19 (1997) 278-285
11. Bell D., Chomarat P., Broyles D., Netto G., Harb G., Lebecque S., Valladeau J., Davoust J., Palucka K., and Banchereau J. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J. Exp. Med. 190 (1999) 1417-1425
12. Bendandi M., Gocke C., Kobrin C., Benko F., Sternas L., Pennington R., Watson T., Reynolds C., Gause B., Duffey P., Jaffe E., Creekmore S., et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nature Med. 5 (1999) 1171-1177
13. Berkner K.L. Development of adenovirus vectors for the expression of heterologous genes. Biotechniques 6 (1988) 616-629
14. Boon T., and van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183 (1996) 725-729
15. Borrello I., Sotomayor E., Cooke S., and Levitsky H. A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. Hum. Gene Ther. 10 (1999) 1983-1991
16. Cerundolo V., Hermans I.F., and Salio M. Dendritic cells: A journey from laboratory to clinic. Nat. Immunol. 5 (2004) 7-10
17. Chambers C.A., Kuhns M.S., Egen J.G., and Allison J.P. CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol. 19 (2001) 565-594
18. Chang D.H., Osman K., Connolly J., Kukreja A., Krasovsky J., Pack M., Hutchinson A., Geller M., Liu N., Annable R., Shay J., Kirchhoff K., et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med. 201 (2005) 1503-1517
19. Chen J.L., Stewart-Jones G., Bossi G., Lissin N.M., Wooldridge L., Choi E.M., Held G., Dunbar P.R., Esnouf R.M., Sami M., Boulter J.M., Rizkallah P., et al. Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J. Exp. Med. 201 (2005) 1243-1255
20. Chen Y.-T., Gure A., Tsang S., Stockert E., Jager E., Knuth A., and Old L. Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc. Natl. Acad. Sci. USA 95 (1998) 6919-6923
21. Clark W., Elder D., Guerry D., Braitman L., Trock B., Schultz D., Synnestvedt M., and Halpern A. Model predicting survival in stage I melanoma based on tumor progression. J. Natl. Cancer Inst. 81 (1989) 1893-1904
22. Cox A., Skipper J., Chen Y., Henderson R., Darrow T., Shabanowitz J., Englehard V., Hunt D., and Slinghuff C. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264 (1994) 716-719
23. Crnkovic-Mertens I., Hoppe-Seyler F., and Butz K. Induction of apoptosis in tumor cells by siRNA-mediated silencing of the livin/ML-IAP/KIAP gene. Oncogene 22 (2003) 8330-8336
24. Dannull J., Nair S., Su Z., Boczkowski D., DeBeck C., Yang B., Gilboa E., and Vieweg J. Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. Blood 105 (2005) 3206-3213
25. Dave S.S., Wright G., Tan B., Rosenwald A., Gascoyne R.D., Chan W.C., Fisher R.I., Braziel R.M., Rimsza L.M., Grogan T.M., Miller T.P., LeBlanc M., et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N. Engl. J. Med. 351 (2004) 2159-2169
26. Davis I.D., Chen W., Jackson H., Parente P., Shackleton M., Hopkins W., Chen Q., Dimopoulos N., Luke T., Murphy R., Scott A.M., Maraskovsky E., et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc. Natl. Acad. Sci. USA 101 (2004) 10697-10702
27. Diefenbach A., and Raulet D. The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol. Rev. 188 (2002) 9-21
28. Doyle A.M., Mullen A.C., Villarino A.V., Hutchins A.S., High F.A., Lee H.W., Thompson C.B., and Reiner S.L. Induction of cytotoxic T lymphocyte antigen 4 (CTLA-4) restricts clonal expansion of helper T cells. J. Exp. Med. 194 (2001) 893-902
29. Dranoff G. GM-CSF-based cancer vaccines. Immunol. Rev. 188 (2002) 147-154
30. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 4 (2004) 11-22
31. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., Jackson V., Hamada H., Pardoll D., and Mulligan R.C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90 (1993) 3539-3543
32. Dropcho E., Chen Y.-T., Posner J., and Old L. Cloning of a brain protein identified by autoantibodies from a patient with paraneoplastic cerebellar degeneration. Proc. Natl. Acad. Sci. USA 84 (1987) 4552-4556
33. Dudley M.E., Wunderlich J.R., Yang J.C., Sherry R.M., Topalian S.L., Restifo N.P., Royal R.E., Kammula U., White D.E., Mavroukakis S.A., Rogers L.J., Gracia G.J., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23 (2005) 2346-2357
34. Dunn G.P., Old L.J., and Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21 (2004) 137-148
35. Engelhard V.H., Bullock T.N., Colella T.A., Sheasley S.L., and Mullins D.W. Antigens derived from melanocyte differentiation proteins: Self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunol. Rev. 188 (2002) 136-146
36. Fehr T., Skrastina D., Pumpens P., and Zinkernagel R.M. T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles. Proc. Natl. Acad. Sci. USA 95 (1998) 9477-9481
37. Finn O.J. Cancer vaccines: Between the idea and the reality. Nat. Rev. Immunol. 3 (2003) 630-641
38. Fong L., Hou Y., Rivas A., Benike C., Yuen A., Fisher G.A., Davis M.M., and Engleman E.G. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. USA 98 (2001) 8809-8814
39. Fontenot J.D., and Rudensky A.Y. A well adapted regulatory contrivance: Regulatory T cell development and the forkhead family transcription factor Foxp3. Nat. Immunol. 6 (2005) 331-337
40. Forni G., Fujiwara H., Martino F., Hamaoka T., Jemma C., Caretto P., and Giovarelli M. Helper strategy in tumor immunology: Expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy. Cancer Metast. Rev. 7 (1988) 289-309
41. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4 (2004) 941-952
42. Gendler S.J., Lancaster C.A., Taylor-Papadimitriou J., Duhig T., Peat N., Burchell J., Pemberton L., Lalani E.N., and Wilson D. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J. Biol. Chem. 265 (1990) 15286-15293
43. Germeau C., Ma W., Schiavetti F., Lurquin C., Henry E., Vigneron N., Brasseur F., Lethe B., De Plaen E., Velu T., Boon T., and Coulie P.G. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J. Exp. Med. 201 (2005) 241-248
44. Getlawi F., Laslop A., Schagger H., Ludwig J., Haywood J., and Apps D. Chromaffin granule membrane glycoprotein IV is identical with Ac45, a membrane-integral subunit of the granule's H(+)-ATPase. Neurosci. Lett. 219 (1996) 13-16
45. Gilboa E. The makings of a tumor rejection antigen. Immunity 11 (1999) 263-270
46. Gilboa E. The promise of cancer vaccines. Nat. Rev. Cancer 4 (2004) 401-411
47. Gillessen S., Naumov Y.N., Nieuwenhuis E.E., Exley M.A., Lee F.S., Mach N., Luster A.D., Blumberg R.S., Taniguchi M., Balk S.P., Strominger J.L., Dranoff G., et al. CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion. Proc. Natl. Acad. Sci. USA 100 (2003) 8874-8879
48. Greenwald R.J., Freeman G.J., and Sharpe A.H. The B7 family revisited. Annu. Rev. Immunol. 23 (2005) 515-548
49. Haanen J.B., Baars A., Gomez R., Weder P., Smits M., de Gruijl T.D., von Blomberg B.M., Bloemena E., Scheper R.J., van Ham S.M., Pinedo H.M., and van den Eertwegh A.J. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol. Immunother. (2005) 1-8
50. Hariu H., Hirohashi Y., Torigoe T., Asanuma H., Hariu M., Tamura Y., Aketa K., Nabeta C., Nakanishi K., Kamiguchi K., Mano Y., Kitamura H., et al. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer. Clin. Cancer Res. 11 (2005) 1000-1009
51. Heibein J.A., Goping I.S., Barry M., Pinkoski M.J., Shore G.C., Green D.R., and Bleackley R.C. Granzyme B-mediated cytochrome c release is regulated by the Bcl-2 family members bid and Bax. J. Exp. Med. 192 (2000) 1391-1402
52. Herman A.E., Freeman G.J., Mathis D., and Benoist C. CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J. Exp. Med. 199 (2004) 1479-1489
53. Hirohashi Y., Torigoe T., Maeda A., Nabeta Y., Kamiguchi K., Sato T., Yoda J., Ikeda H., Hirata K., Yamanaka N., and Sato N. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin. Cancer Res. 8 (2002) 1731-1739
54. Hodi F.S., Mihm M.C., Soiffer R.J., Haluska F.G., Butler M., Seiden M.V., Davis T., Henry-Spires R., MacRae S., Willman A., Padera R., Jaklitsch M.T., et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. USA 100 (2003) 4712-4717
55. Hodi F.S., Schmollinger J.C., Soiffer R.J., Salgia R., Lynch T., Ritz J., Alyea E.P., Yang J.C., Neuberg D., Mihm M., and Dranoff G. ATP6S1 elicits potent humoral responses associated with immune mediated tumor destruction. Proc. Natl. Acad. Sci. USA 99 (2002) 6919-6924
56. Holthuis J.C., Jansen E.J., Schoonderwoert V.T., Burbach J.P., and Martens G.J. Biosynthesis of the vacuolar H+-ATPase accessory subunit Ac45 in Xenopus pituitary. Eur. J. Biochem. 262 (1999) 484-491
57. Holthuis J.C., Jansen E.J., van Riel M.C., and Martens G.J. Molecular probing of the secretory pathway in peptide hormone-producing cells. J. Cell Sci. 108 (1995) 3295-3305
58. Hori S., Takahashi T., and Sakaguchi S. Control of autoimmunity by naturally arising regulatory CD4+ T cells. Adv. Immunol. 81 (2003) 331-371
59. Huang A.Y., Golumbek P., Ahmadzadeh M., Jaffee E., Pardoll D., and Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264 (1994) 961-965
60. + T cells in the antitumor immune response. J. Exp. Med. 188 (1998) 2357-2368
61. Hurwitz A., Yu T., Leach D., and Allison J. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl. Acad. Sci. USA 95 (1998) 10067-10071
62. Hurwitz A.A., Foster B.A., Kwon E.D., Truong T., Choi E.M., Greenberg N.M., Burg M.B., and Allison J.P. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 60 (2000) 2444-2448
63. Iwai Y., Ishida M., Tanaka Y., Okazaki T., Honjo T., and Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. USA 99 (2002) 12293-12297
64. Jaffee E., Hruban R., Biedrzycki B., Laheru D., Schepers K., Sauter P., Goemann M., Coleman J., Grochow L., Donehower R., Lillemoe K., O'Reilly S., et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation. J. Clin. Oncol. 19 (2001) 145-156
65. Jäger E., Ringhoffer M., Altmannsberger M., Arand M., Karbach J., Jäger D., Oesch F., and Knuth A. Immuno-selection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma 71 (1997) 142-147
66. Jansen E.J., Holthuis J.C., McGrouther C., Burbach J.P., and Martens G.J. Intracellular trafficking of the vacuolar H+-ATPase accessory subunit Ac45. J. Cell Sci. 111 (1998) 2999-3006
67. Kasof G.M., and Gomes B.C. Livin, a novel inhibitor-of-apoptosis (IAP) family member. J. Biol. Chem. 276 (2000) 3238-3246
68. Khong H.T., Wang Q.J., and Rosenberg S.A. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: Tumor escape by antigen loss and loss of MHC expression. J. Immunother. 27 (2004) 184-190
69. Klebanoff C.A., Finkelstein S.E., Surman D.R., Lichtman M.K., Gattinoni L., Theoret M.R., Grewal N., Spiess P.J., Antony P.A., Palmer D.C., Tagaya Y., Rosenberg S.A., et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc. Natl. Acad. Sci. USA 101 (2004) 1969-1974
70. Korn W.M., Yasutake T., Kuo W.L., Warren R.S., Collins C., Tomita M., Gray J., and Waldman F.M. Chromosome arm 20q gains and other genomic alterations in colorectal cancer metastatic to liver, as analyzed by comparative genomic hybridization and fluorescence in situ hybridization. Genes Chromosomes Cancer 25 (1999) 82-90
71. Krieg A.M. CpG motifs: The active ingredient in bacterial extracts?. Nat. Med. 9 (2003) 831-835
72. Kusmartsev S., Cheng F., Yu B., Nefedova Y., Sotomayor E., Lush R., and Gabrilovich D. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 63 (2003) 4441-4449
73. Kwon B., Lee H.W., and Kwon B.S. New insights into the role of 4-1BB in immune responses: Beyond CD8+ T cells. Trends Immunol. 23 (2002) 378-380
74. Kwon E.D., Hurwitz A.A., Foster B.A., Madias C., Feldhaus A.L., Greenberg N.M., Burg M.B., and Allison J.P. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc. Natl. Acad. Sci. USA 94 (1997) 8099-8103
75. Laheru D., and Jaffee E.M. Immunotherapy for pancreatic cancer - science driving clinical progress. Nat. Rev. Cancer 5 (2005) 459-467
76. Leach D.R., Krummel M.F., and Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271 (1996) 1734-1736
77. Lin J.-H., Deng G., Huang Q., and Morser J. KIAP, a novel member of the inhibitor of apoptosis protein family. Biochem. Biophys. Res. Comm. 279 (2000) 820-831
78. Liston P., Fong W.G., and Korneluk R.G. The inhibitors of apoptosis: There is more to life than Bcl2. Oncogene 22 (2003) 8568-8580
79. Mach N., and Dranoff G. Cytokine-secreting tumor cell vaccines. Curr. Opin. Immunol. 12 (2000) 571-575
80. Mach N., Gillessen S., Wilson S.B., Sheehan C., Mihm M., and Dranoff G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or flt3-ligand. Cancer Res. 60 (2000) 3239-3246
81. Manis J., Tian M., and Alt F. Mechanism and control of class-switch recombination. Trends Immunol. 23 (2002) 31-39
82. Mihm M., Clemente C., and Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases-A histopathologic prognostic indicator and an expression of local immune response. Lab. Invest. 74 (1996) 43-47
83. Mokyr M.B., Kalinichenko T., Gorelik L., and Bluestone J.A. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Cancer Res. 58 (1998) 5301-5304
84. Mollick J.A., Hodi F.S., Soiffer R.J., Nadler L.M., and Dranoff G. MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients. Cancer Immunity 3 (2003) 3-20
85. Mulligan R.C. The basic science of gene therapy. Science 260 (1993) 926-932
86. Munz C., Steinman R.M., and Fujii S. Dendritic cell maturation by innate lymphocytes: Coordinated stimulation of innate and adaptive immunity. J. Exp. Med. 202 (2005) 203-207
87. Nachmias B., Ashhab Y., Bucholtz V., Drize O., Kadouri L., Lotem M., Peretz T., Mandelboim O., and Ben-Yehuda D. Caspase-mediated cleavage converts Livin from an antiapoptotic to a proapoptotic factor: Implications for drug-resistant melanoma. Cancer Res. 63 (2003) 6340-6349
88. Naito Y., Saito K., Shiiba K., Ohuchi A., Saigenji K., Nagura H., and Ohtani H. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 58 (1998) 3491-3494
89. Nakano O., Sato M., Naito Y., Suzuki K., Orikasa S., Aizawa M., Suzuki Y., Shintaku I., Nagura H., and Ohtani H. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: Clinicopathologic demonstration of antitumor immunity. Cancer Res. 61 (2001) 5132-5136
90. Nemunaitis J., Sterman D., Jablons D., Smith II J.W., Fox B., Maples P., Hamilton S., Borellini F., Lin A., Morali S., and Hege K. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J. Natl. Cancer Inst. 96 (2004) 326-331
91. Ochs H.D., Ziegler S.F., and Torgerson T.R. FOXP3 acts as a rheostat of the immune response. Immunol. Rev. 203 (2005) 156-164
92. Old L. Cancer immunology: The search for specificity-G.H.A. Clowes memorial lecture. Cancer Res. 41 (1981) 361-375
93. Old L., and Chen Y.-T. New paths in human cancer serology. J. Exp. Med. 187 (1998) 1163-1167
94. Paczesny S., Ueno H., Fay J., Banchereau J., and Palucka A.K. Dendritic cells as vectors for immunotherapy of cancer. Semin. Cancer Biol. 13 (2003) 439-447
95. Palucka A.K., Laupeze B., Aspord C., Saito H., Jego G., Fay J., Paczesny S., Pascual V., and Banchereau J. Immunotherapy via dendritic cells. Adv. Exp. Med. Biol. 560 (2005) 105-114
96. Pardoll D.M. Spinning molecular immunology into successful immunotherapy. Nat. Rev. Immunol. 2 (2002) 227-238
97. Parker K.C., Bednarek M.A., and Coligan J.E. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152 (1994) 163-175
98. Phan G.Q., Yang J.C., Sherry R.M., Hwu P., Topalian S.L., Schwartzentruber D.J., Restifo N.P., Haworth L.R., Seipp C.A., Freezer L.J., Morton K.E., Mavroukakis S.A., et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 100 (2003) 8372-8377
99. Reilly R., Machiels J.-P., Emens L., Ercolini A., Okoye F., Lei R., Weintraub D., and Jaffee E. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res. 61 (2001) 880-883
100. Riker A., Cormier J., Panelli M., Kammula U., Wang E., Abati A., Fetsch P., Lee K.H., Steinberg S., Rosenberg S., and Marincola F. Immune selection after antigen-specific immunotherapy of melanoma. Surgery 126 (1999) 112-120
101. Rimoldi D., Rubio-Godoy V., Dutoit V., Lienard D., Salvi S., Guillaume P., Speiser D., Stockert E., Spagnoli G., Servis C., Cerottini J.C., Lejeune F., et al. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma. J. Immunol. 165 (2000) 7253-7261
102. Rohayem J., Diestelkoetter P., Weigle B., Oehmichen A., Schmitz M., Melhorn J., Conrad K., and Rieber E. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res. 60 (2000) 1815-1817
103. Ronsin C., Chung-Scott V., Poullion I., Aknouche N., Gaudin C., and Triebel F. A non-AUG-defined alternative open reading frame of the intestinal carboxyl esterase mRNA generates an epitope recognized by renal cell carcinoma-reactive tumor-infiltrating lymphocytes in situ. J. Immunol. 163 (1999) 483-490
104. Rosenberg S.A. Progress in human tumour immunology and immunotherapy. Nature 411 (2001) 380-384
105. Sahin U., Tureci O., Schmitt H., Cochlovius B., Johannes T., Schmits R., Stenner F., Luo G.R., Schobert I., and Pfreundschuh M. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl. Acad. Sci. USA 92 (1995) 11810-11813
106. Salgia R., Lynch T., Skarin A., Lucca J., Lynch C., Jung K., Hodi F.S., Jaklitsch M., Mentzer S., Swanson S., Lukanich J., Bueno R., et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J. Clin. Oncol. 21 (2003) 624-630
107. Salomon B., and Bluestone J.A. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19 (2001) 225-252
108. Sanderson K., Scotland R., Lee P., Liu D., Groshen S., Snively J., Sian S., Nichol G., Davis T., Keler T., Yellin M., and Weber J. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J. Clin. Oncol. 23 (2005) 741-750
109. Sanna M.G., da Silva Correia J., Ducrey O., Lee J., Nomoto K., Schrantz N., Deveraux Q.L., and Ulevitch R.J. IAP suppression of apoptosis involves distinct mechanisms: The TAK1/JNK1 signaling cascade and caspase inhibition. Mol. Cell Biol. 22 (2002) 1754-1766
110. Schmollinger J.C., and Dranoff G. Targeting melanoma inhibitor of apoptosis protein with cancer immunotherapy. Apoptosis 9 (2004) 309-313
111. Schmollinger J.C., Vonderheide R.H., Hoar K.M., Maecker B., Schultze J.L., Hodi F.S., Soiffer R.J., Jung K., Kuroda M.J., Letvin N.L., Greenfield E.A., Mihm M., et al. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc. Natl. Acad. Sci. USA 100 (2003) 3398-3403
112. Schoonderwoert V.T., Holthuis J.C., Tanaka S., Tooze S.A., and Martens G.J. Inhibition of the vacuolar H+-ATPase perturbs the transport, sorting, processing and release of regulated secretory proteins. Eur. J. Biochem. 267 (2000) 5646-5654
113. Schultze J.L., Grabbe S., and von Bergwelt-Baildon M.S. DCs and CD40-activated B cells: Current and future avenues to cellular cancer immunotherapy. Trends Immunol. 25 (2004) 659-664
114. Shenk T. Adenoviridae: The viruses and their replication. In: Fields B.N., Knipe D.M., and Howley P.M. (Eds). "Fields Virology" (1996), Lippincott-Raven Publishers, Philadelphia 2111-2148
115. Shichijo S., Nakao M., Imai Y., Takasu H., Kawamoto M., Niiya F., Yang D., Toh Y., Yamana H., and Itoh K. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J. Exp. Med. 187 (1998) 277-288
116. Shimizu J., Yamazaki S., and Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: A common basis between tumor immunity and autoimmunity. J. Immunol. 163 (1999) 5211-5218
117. Siddiqui J., Abe M., Hayes D., Shani E., Yunis E., and Kufe D. Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen. Proc. Natl. Acad. Sci. USA 85 (1988) 2320-2325
118. Simons J., Mikhak B., Chang J.-F., DeMarzo A., Carducci M., Lim M., Weber C., Baccala A., Goemann M., Clift S., Ando D., Levitsky H., et al. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 59 (1999) 5160-5168
119. Simons J.W., Jaffee E.M., Weber C.E., Levitsky H.I., Nelson W.G., Carducci M.A., Lazenby A.J., Cohen L.K., Finn C.C., Clift S.M., Hauda K.M., Beck L.A., et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. 57 (1997) 1537-1546
120. Slingluff Jr. C.L., Petroni G.R., Yamshchikov G.V., Barnd D.L., Eastham S., Galavotti H., Patterson J.W., Deacon D.H., Hibbitts S., Teates D., Neese P.Y., Grosh W.W., et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J. Clin. Oncol. 21 (2003) 4016-4026
121. Soiffer R., Hodi F.S., Haluska F., Jung K., Gillessen S., Singer S., Tanabe K., Duda R., Mentzer S., Jaklitsch M., Bueno R., Clift S., et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J. Clin. Oncol. 21 (2003) 3343-3350
122. Soiffer R., Lynch T., Mihm M., Jung K., Rhuda C., Schmollinger J., Hodi F., Liebster L., Lam P., Mentzer S., Singer S., Tanabe K., et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor generates potent anti-tumor immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 95 (1998) 13141-13146
123. Soiffer R.T.L., Mihm M., Jung K., Kolesar K., Liebster L., Lam P., Duda R., Mentzer S., Singer S., Tanabe K., Johnson R., Sober A., et al. A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor. Hum. Gene Ther. 8 (1997) 111-123
124. Srivastava P.K. Peptide-binding heat shock proteins in the endoplasmic reticulum: Role in immune response to cancer and in antigen presentation. Adv. Cancer Res. 62 (1993) 153-177
125. Steinman R.M., and Mellman I. Immunotherapy: Bewitched, bothered, and bewildered no more. Science 305 (2004) 197-200
126. Supek F., Supekova L., Mandiyan S., Pan Y.C., Nelson H., and Nelson N. A novel accessory subunit for vacuolar H(+)-ATPase from chromaffin granules. J. Biol. Chem. 269 (1994) 24102-24106
127. Sutton V.R., Davis J.E., Cancilla M., Johnstone R.W., Ruefli A.A., Sedelies K., Browne K.A., and Trapani J.A. Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation. J. Exp. Med. 192 (2000) 1403-1414
128. Tani K., Azuma M., Nakazaki Y., Oyaizu N., Hase H., Ohata J., Takahashi K., OiwaMonna M., Hanazawa K., Wakumoto Y., Kawai K., Noguchi M., et al. Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: Clinical and immunological findings. Mol. Ther. 10 (2004) 799-816
129. Thomas A.M., Santarsiero L.M., Lutz E.R., Armstrong T.D., Chen Y.C., Huang L.Q., Laheru D.A., Goggins M., Hruban R.H., and Jaffee E.M. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J. Exp. Med. 200 (2004) 297-306
130. Thomas D., Du C., Xu M., Wang X., and Ley T. DFF45/ICAD can be directly processed by granzyme B during the induction of apoptosis. Immunity 12 (2000) 621-632
131. Thompson C.B., and Allison J.P. The emerging role of CTLA-4 as an immune attenuator. Immunity 7 (1997) 445-450
132. Tivol E.A., Borriello F., Schweitzer A.N., Lynch W.P., Bluestone J.A., and Sharpe A.H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3 (1995) 541-547
133. Ueda H., Howson J.M., Esposito L., Heward J., Snook H., Chamberlain G., Rainbow D.B., Hunter K.M., Smith A.N., Di Genova G., Herr M.H., Dahlman I., et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423 (2003) 506-511
134. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., Knuth A., and Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254 (1991) 1643-1647
135. Van Der Bruggen P., Zhang Y., Chaux P., Stroobant V., Panichelli C., Schultz E.S., Chapiro J., Van Den Eynde B.J., Brasseur F., and Boon T. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol. Rev. 188 (2002) 51-64
136. van Elsas A., Hurwitz A., and Allison J. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190 (1999) 355-366
137. van Elsas A., Sutmuller R.P., Hurwitz A.A., Ziskin J., Villasenor J., Medema J.P., Overwijk W.W., Restifo N.P., Melief C.J., Offringa R., and Allison J.P. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: Comparison of prophylaxis and therapy. J. Exp. Med. 194 (2001) 481-489
138. von Mensdorff-Pouilly S., Verstraeten A.A., Kenemans P., Snijdewint F.G., Kok A., Van Kamp G.J., Paul M.A., Van Diest P.J., Meijer S., and Hilgers J. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J. Clin. Oncol. 18 (2000) 574-583
139. Vonderheide R.H., and June C.H. A translational bridge to cancer immunotherapy: Exploiting costimulation and target antigens for active and passive T cell immunotherapy. Immunol. Res. 27 (2003) 341-356
140. Vucic D., Franklin M.C., Wallweber H.J., Das K., Eckelman B.P., Shin H., Elliott L.O., Kadkhodayan S., Deshayes K., Salvesen G.S., and Fairbrother W.J. Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: Implications for Smac-dependent anti-apoptotic activity of ML-IAP. Biochem. J. 385 (2005) 11-20
141. Vucic D., Stennicke H., Pisabarro M., Salvesen G., and Dixit V. ML-IAP, a novel inhibitor of apoptosis that is preferentialy expressed in human melanomas. Curr. Biol. 10 (2000) 1359-1366
142. Wang R., Parkhurst M., Kawakami Y., Robbins P., and Rosenberg S. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J. Exp. Med. 183 (1996) 1131-1140
143. Wang R.-F., Johnston S., Zeng G., Topalian S.L., Schwartzentruber D.J., and Rosenberg S. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J. Immunol. 161 (1998) 3596-3606
144. Waterhouse P., Penninger J.M., Timms E., Wakeham A., Shahinian A., Lee K.P., Thompson C.B., Griesser H., and Mak T.W. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270 (1995) 985-988
145. Watts T.H. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23 (2005) 23-68
146. Wu C., Yang X.-F., McLaughlin S., Neuberg D., Canning C., Stein B., Alyea E., Soiffer R., Dranoff G., and Ritz J. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J. Clin. Invest. 106 (2000) 705-714
147. Yagihashi A., Asanuma K., Kobayashi D., Tsuji N., Shijubo Y., Abe S., Hirohashi Y., Torigoe T., Sato N., and Watanabe N. Detection of autoantibodies to livin and survivin in sera from lung cancer patients. Lung Cancer 48 (2005) 217-221
148. Yagihashi A., Asanuma K., Tsuji N., Torigoe T., Sato N., Hirata K., and Watanabe N. Detection of anti-livin antibody in gastrointestinal cancer patients. Clin. Chem. 49 (2003) 1206-1208
149. Yagihashi A., Ohmura T., Asanuma K., Kobayashi D., Tsuji N., Torigoe T., Sato N., Hirata K., and Watanabe N. Detection of autoantibodies to survivin and livin in sera from patients with breast cancer. Clin. Chim. Acta 362 (2005) 125-130
150. Yang Y.F., Zou J.P., Mu J., Wijesuriya R., Ono S., Walunas T., Bluestone J., Fujiwara H., and Hamaoka T. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: The effect is manifested only at the restricted tumor-bearing stages. Cancer Res. 57 (1997) 4036-4041
151. Yee C., Thompson J.A., Byrd D., Riddell S.R., Roche P., Celis E., and Greenberg P.D. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99 (2002) 16168-16173
152. Young J.W., and Inaba K. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J. Exp. Med. 183 (1996) 7-11
153. Zagon I.S., Verderame M.F., Allen S.S., and McLaughlin P.J. Cloning, sequencing, chromosomal location, and function of cDNAs encoding an opioid growth factor receptor (OGFr) in humans. Brain Res. 856 (2000) 75-83
154. Zeng R., Spolski R., Finkelstein S.E., Oh S., Kovanen P.E., Hinrichs C.S., Pise-Masison C.A., Radonovich M.F., Brady J.N., Restifo N.P., Berzofsky J.A., and Leonard W.J. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J. Exp. Med. 201 (2005) 139-148
155. Zhang D., Beresford P.J., Greenberg A.H., and Lieberman J. Granzymes A and B directly cleave lamins and disrupt the nuclear lamina during granule-mediated cytolysis. Proc. Natl. Acad. Sci. USA 98 (2001) 5746-5751
156. Zhang L., Conejo-Garcia J., Katsaros D., Gimotty P., Massobrio M., Regnani G., Makrigiannakis A., Gray H., Schlienger K., Liebman M., Rubin S., and Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Eng. J. Med. 348 (2003) 203-213